Nature Medicine
3, 154 - 155 (1997)
doi:10.1038/nm0297-154
Platelet stimulating agents — off the launching padStephen D. NimerMemorial Sloan-Kettering Cancer Center, New York, New York 10021, USA Promising clinical trial data suggest that thrombopoietic growth factors may soon enter clinical practice.
REFERENCES
- Metcalf, D. Thrombopoietin − at last. Nature 369, 519−520 (1994). | Article | PubMed | ISI | ChemPort |
- Gurney, A.L., Carver-Moore, K., de Sauvage, F.J. & Moore, M.W. Thrombocytopenia in c-mpl-deficient mice. Science 265, 1445−1447 (1994). | PubMed | ISI | ChemPort |
- de Sauvage, F. et al. Physiological regulation of early and late stages of megakaryocytopoiesis by thrombopoietin. J. Exp. Med. 183, 651−656 (1996). | PubMed | ChemPort |
- Kaushansky, K. et al. Thrombopoietin, the mpl lig-and, is essential for full megakaryocyte develop-ment. Proc. Natl. Acad. Sci. USA 92, 3234−3238 (1995). | PubMed | ChemPort |
- Shivdasani, R.A. et al. Transcription factor NF-E2 is required for platelet formation independent of the actions of thrombopoietin/MCDF in megakary-ocyte development. Cell 81, 695−704 (1995). | PubMed | ISI | ChemPort |
- Tepler, I. et al. A randomized placebo-controlled trial of recombinant human interleukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy. Blood 87, 3607−3614 (1996). | PubMed | ISI | ChemPort |
- Basser, R.L. et al. Thrombopoietic effects of pegy-lated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in patients with advanced cancer. Lancet 348, 1279−1281 (1996). | Article | PubMed | ISI | ChemPort |
- Archimbaud, E. et al. A randomized, double-blind, placebo-controlled study using PEG-rHuMGDF as an adjunct to chemotherapy for adults with de novo acute myeloid leukemia (AML): Early results (Abstr.). Blood 88, (Suppl. 1), 447a (1996).
- Vadhan-Raj, S. et al. Phase l-ll investigation of re-combinant human thrombopoietin (rhTPO) in pa-tients with sarcoma receiving high dose chemotherapy (CT) with adriamycin (A) and ifos-famide (I) (Abstr.). Blood 88, (Suppl. 1), 448a (1996).
- O'Malley, C.J. et al. Administration of pegylated recombinant human megakaryocyte growth and development factor to humans stimulates the production of functional platelets that show no evidence of in vitro activation. Blood 88, 3288−3298 (1996). | PubMed | ChemPort |
- Groopman, J.E., Mitsuyasu, R.T., DeLeo, M.J., Oette, D.H. & Golde, D.W. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on myelopoiesis in the acquired immunodeficiency syndrome. New Engl. J. Med. 317, 593−598 (1987). | PubMed | ISI | ChemPort |
|
